Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
13.4.2021 15:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) announced the initiation of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH). The compound was in-licensed from Zealand in 2011 and is being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus. The once-weekly therapy may offer additional benefits on both chronic weight management, and NASH improvement and prevention of the progression to cirrhosis compared to currently available treatments with mono GLP-1 agonist compounds. BI 456906 is part of Boehringer Ingelheim’s growing portfolio in the obesity and NASH disease areas.
“Obesity and NASH are areas of high unmet medical need, with limited approved treatments currently available. They are associated with lower quality of life and increased mortality,” explains Prof. Arun J. Sanyal, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine in Richmond, Virginia. “I hope that this new approach will bring a much-needed treatment option for HCPs and people afflicted with obesity or NASH.”
Boehringer Ingelheim and Zealand have a fruitful longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases. “We are very excited to see the initiation of Phase 2 trials of BI 456906 for obesity and NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining GLP-1 and glucagon agonism mechanistically, we believe our dual agonist has the potential to achieve increased weight loss, via improvement of the patient’s metabolism, and also has potential to alleviate NASH by reducing upstream steatosis.”
“Our cardiometabolic research and development is focusing on discovering novel treatments for obesity and non-alcoholic steatohepatitis (NASH), to meet the large unmet need among these groups,” explains Waheed Jamal, MD, Head of Cardiovascular, Metabolic and Respiratory Medicine at Boehringer Ingelheim. “We are exploring a number of unique approaches with great potential to help people living with obesity or NASH. We believe dual agonists are next generation drug candidates with a potential for higher efficacy in weight loss and NASH improvement/cirrhosis prevention.”
Under the terms of the GLP-1/glucagon dual agonist licensing agreement, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is entitled to receive up to EUR 345 million in outstanding milestone payments. No milestone payments are due with the initiations of these Phase 2 studies. The agreement also carries high-single digit to low-double digit percentage royalties on global sales.
Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/clinical-phase2-trials-nash-and-obesity
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005636/en/
Contact information
Boehringer Ingelheim
Dr. Birgit Leimer
Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
E-Mail: press@boehringer-ingelheim.com
Zealand Pharma
David Rosen
Argot Partners
E-Mail: media@zealandpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Planning Events Just Got Easier: Navan Launches Unified Events Platform22.6.2026 14:43:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today launched Navan Events. The unified platform streamlines venue sourcing, attendee travel, and financial reporting for corporate meetings and events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622642039/en/ All-in-one solution integrates venue sourcing, travel booking, event management and spending analytics Legacy event management relies on manual processes and patchwork tools, creating administrative friction and compliance challenges. Navan Events aims to solve these problems by centralizing the entire event lifecycle into one seamless experience. "Navan makes life easier for our users so they can focus on being there versus getting there," said Galen Grady, SVP and GM of Navan Events. "Nothing replaces real, in-person connections, but planning and coordinating events can be a major time suck. Our customers want the same seamless
ScottsMiracle-Gro Cultivates End-to-End Supply Chain Agility with Kinaxis22.6.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that ScottsMiracle-Gro, the leading marketer of branded consumer lawn and garden products in North America, is expanding its partnership with Kinaxis. The move will further optimize its supply chain planning operations as part of a broader transformation initiative, building on proven success and results achieved in recent years. Operating in a seasonal environment, where demand can be impacted by regional weather patterns, retailer promotions, and shifting consumer behavior, ScottsMiracle-Gro is investing further in the Kinaxis Maestro™ platform to improve planning accuracy and strengthen end-to-end supply chain orchestration across its North American network. This transformation reflects the company’s focus on supply chain technology as a foundational necessity. By connecting planning, decision-making, and execution on a unified platform, the company aims to improve responsiven
NIQ Expands GeoPurchase Audiences Globally, Unlocking Growth Opportunities for Marketers in Poland, Belgium, Mexico, and Indonesia22.6.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its GeoPurchase audiences into Poland, Belgium, Mexico, and Indonesia, extending its purchase-based, geo-targeted audiences to new international markets. As privacy regulations tighten and identifiers like cookies decline, marketers need new ways to reach high-value consumers at scale. NIQ’s GeoPurchase Audiences address this challenge by helping marketers identify and target consumers based on demand, not just demographics. GeoPurchase audiences help marketers pinpoint geographic areas where consumers are most likely to purchase specific FMCG categories, brands, or sub-brands, so media investments can concentrate where retail opportunities are strongest. By focusing investments in priority locations, marketers can connect with the audiences that matter in the markets with the greatest opportunity. As a result, GeoPurchase audiences help marketers improve media efficiency by turning local demand
Smartly Introduces Smartly Synapse, the Intelligent AI Orchestration Layer Powering Its Advertising Platform22.6.2026 13:00:00 EEST | Press release
Smartly today introduced Smartly Synapse, the intelligent AI orchestration and memory layer behind every Smartly AI Agent. Built on years of cross-channel creative, media and performance intelligence and continuously shaped by real-world outcomes, Smartly Synapse transforms millions of signals into actions that help marketers plan smarter, execute faster and drive stronger business results. Smartly Synapse creates a continuous performance loop where marketer intent, business context, campaign activity and outcomes continuously inform one another. Its shared intelligence and memory layer helps the system learn from every campaign, improving future recommendations, execution and performance. “Smartly Synapse is the intelligent AI orchestration and memory layer behind our AI agents. It augments Smartly’s existing platform, turning campaign data, business context and user input into coordinated action,” said Maxwell Tang, Chief Product Officer, Smartly. “We built Smartly Synapse for brands
Europe’s Original First Check Investor Seedcamp Raises $320 Million22.6.2026 12:23:00 EEST | Press release
Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now returned over 13x DPI to its Limited Partners, and Fund IV sits at over 5x net TVPI. The new capital is allocated between $220m for Seedcamp VII, the flagship first check fund, and $100m for the Select fund, which focuses primarily on backing portfolio winners as they scale toward Series B and beyond. For nearly two decades, Seedcamp has backed founders before they become obvious as the first institutional investor. Many of those companies have gone on to become the largest technology businesses in the wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom